ViVa News — Week 26

Over the last week (≈23–29 June 2026), only a few jurisdictions and agencies released materially new vaccine guidance, with meaningful activity centered on COVID‑19 adult booster policy (Canada, Australia, New Zealand) and US influenza vaccine regulation; WHO issued procedural updates on vaccine prequalification, while major manufacturers reported no new pivotal trial readouts or product approvals in this narrow window. Asia (incl. Southeast Asia, China, India) No new national immunization schedules, NITAG recommendations, or formal vaccine policy statements with immediate programmatic impact were identified this week from major Asian markets, including Southeast Asia, China, and India, in accessible English‑language sources. Australia and New Zealand Australia – COVID-19 and influenza The Australian Immunisation Handbook COVID-19 chapter was updated in late May and remains the operative guidance this week, specifying interval-based booster recommendations by age and risk category. Adults ≥75 years: further COVID‑19 doses every 6 months are recommended. Adults 65–74 years and 18–64 years at higher...